Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families

Pigment Cell Research

Volumn 16, Issue 3, 2003, Pages 208-214

  Alkhateeb, Asem ^a   Fain, Pamela R ^a   Thody, Anthony ^b   Bennett, Dorothy C ^c   Spritz, Richard A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Autoimmunity; Melanocyte; Survey

Indexed keywords

ADDISON DISEASE; ADULT; ALOPECIA AREATA; ARTICLE; AUTOIMMUNITY; CAUCASIAN; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENTERITIS; ETHNOLOGY; FEMALE; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; HYPOTHYROIDISM; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MONOZYGOTIC TWINS; MULTIFACTORIAL INHERITANCE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NORTH AMERICA; ONSET AGE; PERNICIOUS ANEMIA; POPULATION GENETIC PARAMETERS; PSORIASIS; RELATIVE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCLERODERMA; SEX RATIO; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED KINGDOM; VITILIGO;

ADOLESCENT; ADULT; AGE FACTORS; AGE OF ONSET; AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; CHILD; CHILD, PRESCHOOL; DISEASES IN TWINS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; MALE; MIDDLE AGED; MODELS, STATISTICAL; SEX FACTORS; SKIN DISEASES; TIME FACTORS; TWINS, MONOZYGOTIC; VITILIGO;

SCLERODERMA;

EID: 0037986326     PISSN: 08935785     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0749.2003.00032.x     Document Type: Article

References (51)

1. Hann S-K, Nordlund J. Vitiligo. Oxford: Blackwell Science; 2000.
2. Mehta NR, Shah KC, Theodore C, Vyas VP, Patel AB. Epidemiological study of vitiligo in Surat area. Indian J Med Res 1973;61:145-154
3. Carnevale A, Zavala C, Castillo VD, Maldonado RR, Tamayo L. Analisis genetico de 127 families con vitiligo. Rev Invest Clin 1980;32:37-41
4. Hafez M, Sharaf L, El-Nabi SMA. The genetics of vitiligo. Acta Dermatovener (Stockh) 1983;63:249-251
5. Das SK, Majumder PP, Chakraborty R, Majumdar TK, Halder B. Studies on vitiligo. I. Epidemiological profile in Calcutta, India. Genet Epidemiol 1985;2:71-78
6. Das SK, Majumder PP, Majumder TK, Haldar B. Studies on vitiligo. II. Familial aggregation and genetics. Genet Epidemiol 1985;2:255-262
7. Majumder PP, Das SK, Li CC. A genetical model for vitiligo. Am J Hum Genet 1988;43:119-125
8. Bhatia PS, Mohan L, Pandey ON, Singh KK, Arora SK, Mukhija RD. Genetic nature of vitiligo. J Dermatol Sci 1992;4:180-184
9. Majumder PP, Nordlund JJ, Nath SK. Pattern of familial aggregation of vitiligo. Arch Dermatol 1993;129:994-998
10. Nath SK, Majumder PP, Nordlund JJ. Genetic epidemiology of vitiligo: multilocus recessivity cross-validated. Am J Hum Genet 1994;55:981-990
11. Le Poole IC, Sarangarajan R, Zhao Y, Stennett LS, Brown TL, Sheth P, Miki T, Boissy RE. 'VITI', a novel gene associated with vitiligo. Pigment Cell Res 2001;14:475-484
12. Zamani M, Spaepen M, Sghar SS, Huang C, Westerhof W, Nieuweboer-Krobotova L, Cassiman JJ. Linkage and association of HLA class II genes with vitiligo in a Dutch population. Br J Dermatol 2001;145:90-94
13. Alkhateeb A, Stetler GL, Old W, Talbert J, Uhlhorn C, Taylor M, Fox A, Miller C, Dills DG, Ridgway EC. Bennett DC, Fain PR, Spritz RA. Mapping of an autoimmunity susceptibility locus (AISI) to chromosome 1p31.2-p32.2. Hum Mol Genet 2002;11:661-667
14. Harsoulis P, Kanakoudi-Tsakalidis F, Vyzantiadis A, Minas A, Cassimos C. Autoimmunity and vitiligo. Arch Dermatol 1978;114:1554
15. Nordlund JJ, Halder RM, Grimes P. Management of vitiligo. Dermatol Clin 1993;11:27-33
16. Ortonne J-P, Bose SK. Vitiligo: where do we stand? Pigment Cell Res 1993;6:61-72
17. Nordlund JJ, Ortonne J-P. Vitiligo vulgaris. In: Nordlund JJ, Boissy RE, Hearing VJ, King RA, Ortonne J-P. The Pigmentary System. Oxford, New York: Oxford University Press; 1998. pp. 513-551
18. Ongenai K, Van Geel N, Naeyaert J-M. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003;16:90-100
19. Naughton G, Eisinger M, Bystryn J. Antibodies to normal human melanocytes in vitiligo. J Exp Med 1983;158:246-251
20. Naughton G, Eisinger M, Bystryn J. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. J Invest Dermatol 1983;81:540-542
21. Naughton G, Reggiardo D, Bystryn J. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986;15:978-981
22. Galbraith GM, Miller D, Emerson DL. Western blot analysis of serum antibody reactivity with human melanoma cell antigens in alopecia areata and vitiligo. Clin Immunol Immunolpath 1988;48:317-324
23. Norris D, Kissinger M, Naughton G, Bystryn JC. Evidence for immunologic mechanisms in human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 1988;90:783-789
24. Harning R, Cui J, Bystryn J-C. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 1991;97:1078-1080
25. Cui J, Arita Y, Bystryn J-C. Cytolytic antibodies to melanocytes in vitiligo. J Invest Dermatol 1993;100:812-815
26. Kemp E, Gawkrodger D, MacNeil S. Detection of tyrosinase autoantibodies in patients with vitiligo using 35S-labeled recombinant human tyrosinase in a radioimmunoassay. J Invest Dermatol 1997;109:69-73
27. Kemp E, Gawkrodger D, Watson P, Weetman AP. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). Clin Exp Immunol 1997;109:495-500
28. Abdel-Nasser MB, Kruger-Krasagakes S, Krasagakis K, Gollnick H, Abdel-Fattah H, Orfanos CE. Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo. Pigment Cell Res 1994;7:1-8
29. Durham-Pierre DG, Walters CS, Halder RM. Natural killer cell and lymphokine-activated killer cell activity against melanocytes in vitiligo. J Am Acad Dermatol 1995;33:26-30
30. Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J Exp Med 2000;192:1637-1644
31. Nagai H, Hara I, Horikawa T, Oka M, Kamidono S, Ichihashi M. Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligolike coat alteration. J Invest Dermatol 2000;115:1059-1064
32. Baker JR Jr. Immunologic aspects of endocrine diseases. J Am Med Assoc 1992;268:2899-2903
33. Riley WJ. Autoimmune polyglandular syndromes. Horm Res 1992;38:9-15
34. Cunliffe W, Hall R, Newell J, Stevenson CJ. Vitiligo, thyroid disease and autoimmunity. Br J Dermatol 1968;80:135-139
35. Schallreuter KW, Lemke R, Brandt O, Schwartz R, Westhofen M, Montz R, Berger J. Vitiligo and other diseases: coexistence or true association? Dermatol 1994;188:269-275
36. Dawber R. Integumentary associations of pernicious anemia. Br J Dermatol 1969;82:221-222
37. Grunnet I, Howitz J. Vitiligo and pernicious anemia. Arch Dermatol 1970;101:82-85
38. Zelissen PMJ, Bast EJEG, Croughs RJM. Associated autoimmunity in Addison's disease. J Autoimmunity 1995;8:121-130
39. Sharma VK, Dawn G, Kumar B. Profile of alopecia areata in Northern India. Int J Dermatol 1996;35:22-27
40. Sharma VK, Kumar V, Dawn G. A clinical study of childhood alopecia areata in Chandigarh, India. Pediatr Dermatol 1996;13:372-377
41. Colton T. Statistics in Medicine. Boston: Little Brown; 1974.
42. Howitz J, Brodthagen H, Schwartz M, Thompsen K. Prevalence of vitiligo: epidemiological survey of the Isle of Bornholm, Denmark. Arch Dermatol 1977;113:47-52
43. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopath 1997;84:223-243
44. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000;160:526-534
45. 4, and thyroid antibodies in the United States population (1988-94): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrin Metab 2002;87:489-499
46. Weiss KM, Chakraborty P, Majumder PP, Smouse P. Problems in the assessment of relative risk of chronic disease among biological relatives of affected individuals. J Chronic Dis 1982;35:539-553
47. Safavi K. Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. Arch Dermatol 1992;128:702
48. Safavi K, Muller S, Suman V, Moshell AN, Melton LJ 3rd. Incidence of alopecia areata in Olmsted county Minnesota, 1975 through 1989. Mayo Clin Proc 1995;70:628-633
49. Loftus EV, Sandborn WJ. The epidemiology of inflammatory bowel disease. Gastroenterol Clin N Am 2002;31:1-20
50. Loftus EV, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, survival. Gut 2000;46:336-343
51. Farber EM, Nall MI. Epidemiology: natural history and genetics. In: Roenigk HH, Maibach HI. Psoriasis. New York: Marcel Dekker; 1998: pp. 107-158